z-logo
open-access-imgOpen Access
Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action
Author(s) -
Amaury E. FernándezMontalván,
Markus Berger,
Benno Kuropka,
Seong Joo Koo,
Volker Badock,
Joerg Weiske,
Vera Puetter,
Simon J. Holton,
Detlef Stöckigt,
Antonius ter Laak,
Paolo A. Centrella,
Matthew Clark,
Christoph E. Dumelin,
Eric A. Sigel,
Holly H. Soutter,
Dawn M. Troast,
Ying Zhang,
John W. Cuozzo,
Anthony D. Keefe,
Didier Roche,
Vincent Rodeschini,
A. Chaikuad,
L. Diaz Saez,
James M. Bennett,
Oleg Fedorov,
K. Huber,
Jan Hübner,
Hilmar Weinmann,
Ingo V. Hartung,
Mátyás Gorjánácz
Publication year - 2017
Publication title -
acs chemical biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.899
H-Index - 111
eISSN - 1554-8937
pISSN - 1554-8929
DOI - 10.1021/acschembio.7b00708
Subject(s) - bromodomain , gene isoform , histone , epigenetics , acetylation , chromatin , chemical biology , regulator , mode of action , microbiology and biotechnology , biology , dna , computational biology , chemistry , biochemistry , genetics , gene
ATAD2 (ANCCA) is an epigenetic regulator and transcriptional cofactor, whose overexpression has been linked to the progress of various cancer types. Here, we report a DNA-encoded library screen leading to the discovery of BAY-850, a potent and isoform selective inhibitor that specifically induces ATAD2 bromodomain dimerization and prevents interactions with acetylated histones in vitro, as well as with chromatin in cells. These features qualify BAY-850 as a chemical probe to explore ATAD2 biology.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom